Chemo-immunotherapy with ibrutinib and indoximod for pediatric brain tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This Phase 1 study tests a combination treatment (ibrutinib plus indoximod along with chemotherapy) for children with brain tumors that have come back or are hard to treat. It may help shrink active tumor or control the disease when standard treatments can’t cure it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has a confirmed brain tumor diagnosis (such as ependymoma, medulloblastoma, glioblastoma, or another primary brain/central nervous system cancer) that is growing again or not responding, with no curative treatment option.
- An MRI (with and without contrast dye) must show active tumor right now.
- Your child must be able to swallow pills and take the study medicines by mouth.
- Your child must have “enough strength” for treatment (Lansky/Karnofsky score 50 or higher) and lab results that show kidneys, liver, bone marrow, and blood counts are within required ranges.
- Seizures (if present) must be well controlled on anti-seizure medicine, and you can’t be on other cancer treatments or study medicines not allowed by the protocol while enrolled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral drugs (axitinib and metronomic etoposide) for children and young adults whose medulloblastoma or ependymoma has come back or is not responding to standard therapy. The goal is to see if this daily pill treatment can control tumor growth with manageable side effects.
This trial tests a new immune therapy using your child's own specially trained white blood cells to fight brain tumors. The treatment is given directly into the fluid around the brain, and it is for children with specific types of brain cancer.
This trial tests whether adding a thyroid hormone (liothyronine) to a standard chemotherapy combination (bevacizumab, irinotecan, temozolomide) can help children and young adults with medulloblastoma that has come back after initial treatment.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
This Phase 2 study tests a combination of chemotherapy and radiation after surgery for certain brain tumors that are “IDH wildtype.” It aims to control the tumor and improve outcomes for people with specific types of glioma or glioblastoma.
This trial tests an experimental drug called NLG802 combined with the chemotherapy drug temozolomide for children and young adults whose brain or spinal cancer has come back or has not responded to treatment. The goal is to see if this combination can help shrink tumors or slow their growth.
Hear when a new Ependymoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.